• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

罕见和超罕见人类疾病中的无义突变:概述

Nonsense Mutations in Rare and Ultra-Rare Human Disorders: An Overview.

作者信息

Vitale Emanuele, Ricci Davide, Corrao Federica, Fiduccia Ignazio, Cruciata Ilenia, Carollo Pietro Salvatore, Branchini Alessio, Lentini Laura, Pibiri Ivana

机构信息

Department of Biological, Chemical and Pharmaceutical Sciences and Technologies, University of Palermo, Palermo, Italy.

Department of Life Sciences and Biotechnology and LTTA Centre, University of Ferrara, Ferrara, Italy.

出版信息

IUBMB Life. 2025 Jun;77(6):e70031. doi: 10.1002/iub.70031.

DOI:10.1002/iub.70031
PMID:40474765
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12142302/
Abstract

Over 7000 rare diseases have been described, collectively affecting 350 million people worldwide. Most of these conditions result from nonsense mutations, representing approximately 10% of all genetic mutations associated with human inherited diseases. Nonsense mutations convert a sense codon into a premature termination codon (PTC), leading to premature translation termination and the production of truncated, nonfunctional proteins. This results in a loss-of-function phenotype in many genetic disorders, contributing to the disease's severity and progression. The molecular mechanisms of PTC formation involve various genetic alterations, including single-nucleotide changes, frameshifts, and splicing mutations. The nonsense-mediated mRNA decay (NMD) pathway degrades mRNAs containing premature termination codons (PTCs). In contrast, 25% of PTC mRNAs, depending on the PTC position and cellular context, can evade NMD, resulting in the synthesis of truncated proteins. A termination codon during translation is essential for proper protein synthesis, and translational readthrough-a process in which the ribosome bypasses the PTC and reaches the natural stop codon-may restore some level of protein function. The effectiveness of readthrough depends on the surrounding genetic context and the type of amino acid incorporated at the PTC position. This review aims to explore the molecular characteristics of nonsense-related diseases (NRDs), including cystic fibrosis, hemophilia, Fabry disease, choroideremia, Usher syndrome, Shwachman-Diamond syndrome, and certain hereditary neuropathies and cancers.

摘要

已描述的罕见病超过7000种,全球共有3.5亿人受其影响。这些病症大多由无义突变引起,约占所有与人类遗传性疾病相关基因突变的10%。无义突变将有义密码子转变为过早终止密码子(PTC),导致翻译提前终止并产生截短的、无功能的蛋白质。这在许多遗传疾病中导致功能丧失表型,加剧了疾病的严重程度和进展。PTC形成的分子机制涉及各种基因改变,包括单核苷酸变化、移码突变和剪接突变。无义介导的mRNA降解(NMD)途径会降解含有过早终止密码子(PTC)的mRNA。相反,根据PTC位置和细胞环境,25%的PTC mRNA可逃避NMD,从而导致截短蛋白的合成。翻译过程中的终止密码子对于正确的蛋白质合成至关重要,而翻译通读——核糖体绕过PTC并到达天然终止密码子的过程——可能会恢复一定程度的蛋白质功能。通读的有效性取决于周围的基因环境以及在PTC位置掺入的氨基酸类型。本综述旨在探讨与无义相关疾病(NRD)的分子特征,包括囊性纤维化、血友病、法布里病、脉络膜视网膜炎、乌舍尔综合征、施瓦茨曼-戴蒙德综合征以及某些遗传性神经病和癌症。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c01e/12142302/1c4053f4a3a5/IUB-77-0-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c01e/12142302/1c4053f4a3a5/IUB-77-0-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c01e/12142302/1c4053f4a3a5/IUB-77-0-g001.jpg

相似文献

1
Nonsense Mutations in Rare and Ultra-Rare Human Disorders: An Overview.罕见和超罕见人类疾病中的无义突变:概述
IUBMB Life. 2025 Jun;77(6):e70031. doi: 10.1002/iub.70031.
2
Advancing Therapeutic Strategies for Nonsense-Related Diseases: From Small Molecules to Nucleic Acid-Based Innovations.针对无义相关疾病的先进治疗策略:从小分子到基于核酸的创新
IUBMB Life. 2025 May;77(5):e70027. doi: 10.1002/iub.70027.
3
Emerging Personalized Opportunities for Enhancing Translational Readthrough in Rare Genetic Diseases and Beyond.新兴的个性化机会,用于增强罕见遗传疾病及其他疾病的翻译通读。
Int J Mol Sci. 2023 Mar 23;24(7):6101. doi: 10.3390/ijms24076101.
4
Ataluren and similar compounds (specific therapies for premature termination codon class I mutations) for cystic fibrosis.用于治疗囊性纤维化的阿他芦醇及类似化合物(针对I类提前终止密码子突变的特定疗法)。
Cochrane Database Syst Rev. 2017 Jan 19;1(1):CD012040. doi: 10.1002/14651858.CD012040.pub2.
5
Ataluren and similar compounds (specific therapies for premature termination codon class I mutations) for cystic fibrosis.依伐卡托(Ataluren)及类似化合物(针对 I 类提前终止密码子突变的特异性治疗药物)治疗囊性纤维化。
Cochrane Database Syst Rev. 2023 Mar 3;3(3):CD012040. doi: 10.1002/14651858.CD012040.pub3.
6
Prescription of Controlled Substances: Benefits and Risks管制药品的处方:益处与风险
7
Systematic analysis of nonsense variants uncovers peptide release rate as a novel modifier of nonsense-mediated mRNA decay.对无义变异的系统分析揭示了肽释放速率是无义介导的mRNA衰变的一种新型调节因子。
Cell Genom. 2025 May 13:100882. doi: 10.1016/j.xgen.2025.100882.
8
Nonsense suppression therapies in human genetic diseases.无义抑制疗法在人类遗传疾病中的应用。
Cell Mol Life Sci. 2021 May;78(10):4677-4701. doi: 10.1007/s00018-021-03809-7. Epub 2021 Mar 22.
9
An engineered glutamic acid tRNA for efficient suppression of pathogenic nonsense mutations.一种用于有效抑制致病性无义突变的工程化谷氨酸转运RNA。
Nucleic Acids Res. 2025 Jun 20;53(12). doi: 10.1093/nar/gkaf532.
10
Therapeutics based on stop codon readthrough.基于终止密码子通读的疗法。
Annu Rev Genomics Hum Genet. 2014;15:371-94. doi: 10.1146/annurev-genom-091212-153527. Epub 2014 Apr 18.

本文引用的文献

1
Advancing Therapeutic Strategies for Nonsense-Related Diseases: From Small Molecules to Nucleic Acid-Based Innovations.针对无义相关疾病的先进治疗策略:从小分子到基于核酸的创新
IUBMB Life. 2025 May;77(5):e70027. doi: 10.1002/iub.70027.
2
Engineered tRNAs efficiently suppress CDKL5 premature termination codons.工程化tRNA可有效抑制CDKL5基因的过早终止密码子。
Sci Rep. 2024 Dec 30;14(1):31791. doi: 10.1038/s41598-024-82766-0.
3
Promoting readthrough of nonsense mutations in CF mouse model: Biodistribution and efficacy of NV848 in rescuing CFTR protein expression.
促进囊性纤维化小鼠模型中无义突变的通读:NV848在挽救囊性纤维化跨膜传导调节蛋白(CFTR)表达中的生物分布和疗效
Mol Ther. 2024 Dec 4;32(12):4514-4523. doi: 10.1016/j.ymthe.2024.10.028. Epub 2024 Oct 28.
4
Genome-scale quantification and prediction of pathogenic stop codon readthrough by small molecules.通过小分子对致病性终止密码子通读的全基因组规模定量和预测。
Nat Genet. 2024 Sep;56(9):1914-1924. doi: 10.1038/s41588-024-01878-5. Epub 2024 Aug 22.
5
Clinical and genetic characteristics of Chinese patients with Shwachman Diamond syndrome: a literature review of Chinese publication.中国 Shwachman Diamond 综合征患者的临床和遗传特征:中文文献综述。
Exp Biol Med (Maywood). 2024 Apr 8;249:10035. doi: 10.3389/ebm.2024.10035. eCollection 2024.
6
mRNA therapies: Pioneering a new era in rare genetic disease treatment.信使核糖核酸疗法:开创罕见遗传病治疗的新时代。
J Control Release. 2024 May;369:696-721. doi: 10.1016/j.jconrel.2024.03.056. Epub 2024 Apr 13.
7
Fabry Disease in Women: Genetic Basis, Available Biomarkers, and Clinical Manifestations.女性法布里病:遗传基础、可用生物标志物和临床表现。
Genes (Basel). 2023 Dec 26;15(1):37. doi: 10.3390/genes15010037.
8
Identifying Potent Nonsense-Mediated mRNA Decay Inhibitors with a Novel Screening System.利用新型筛选系统鉴定有效的无义介导的mRNA衰变抑制剂
Biomedicines. 2023 Oct 16;11(10):2801. doi: 10.3390/biomedicines11102801.
9
Ataluren improves myelopoiesis and neutrophil chemotaxis by restoring ribosome biogenesis and reducing p53 levels in Shwachman-Diamond syndrome cells.阿他芦胺通过恢复核糖体生物合成和降低施瓦茨曼-戴蒙德综合征细胞中的p53水平来改善骨髓生成和中性粒细胞趋化性。
Br J Haematol. 2024 Jan;204(1):292-305. doi: 10.1111/bjh.19134. Epub 2023 Oct 24.
10
In vitro and ex vivo rescue of a nonsense mutation responsible for severe coagulation factor V deficiency.体外和体内挽救导致严重凝血因子 V 缺乏的无意义突变。
J Thromb Haemost. 2024 Feb;22(2):410-422. doi: 10.1016/j.jtha.2023.10.007. Epub 2023 Oct 21.